Inhibrx to Present Key Oncology Data at Three Major Scientific Conferences
Event summary
- Inhibrx Biosciences will present data on two lead candidates at three scientific conferences in October and November 2026
- Phase 2/3 data for ordastobart (INBRX-106) in head and neck cancer to be presented at ESMO Congress on October 25, 2026
- Ozekibart (INBRX-109) data in chondrosarcoma and Ewing sarcoma to be presented at MSTS and CTOS meetings
- Presentations will be available on Inhibrx's investor relations website during each event
The big picture
Inhibrx's upcoming conference presentations represent key milestones for its two lead oncology candidates. The data could significantly impact the company's strategic positioning in the competitive immuno-oncology space. With both candidates utilizing proprietary multivalent formats, positive results could validate Inhibrx's protein engineering approach and attract potential partners or investors.
What we're watching
- Clinical Efficacy
- How the Phase 2 primary analysis of ordastobart in head and neck cancer will impact its development trajectory
- Regulatory Pathway
- Whether the ChonDRAgon study data for ozekibart will support potential registration
- Pipeline Diversification
- The pace at which Inhibrx can advance multiple oncology programs simultaneously
